Worldwide markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.
In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).
Request A Sample Copy of This Report at: https://bit.ly/2Lu7PtJ
Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions.
Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.
In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations-the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target-the difference is the greater amount of information gained by visualizing the results within the tissue.
Browse Full Research Report with TOC on https://bit.ly/2PbBtpH
The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017. CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.
Companies Profiled
Market Leaders
• Leica Biosystems Nussloch GmbH
• Thermo Fisher Scientific
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Agilent Technologies
• PerkinElmer
• Qiagen / Exiqon A/S
• Merck KGaA
• BioGenex Laboratories
• BioTechne / Advanced Cell Diagnostics (ACD)
Key Topics
• In Situ Hybridization
• Molecular Diagnostics
• Cervical Cancer Stain
• Fish Steps Reduction
• Fluorescence In Situ Hybridization (FISH)
• In Situ Hybridization (ISH)
• FISH Probe Kit
• Cancer
• Chromosonal Abnormalities
• Infectious Diseases
• Inflammatory Diseases
• Fluorescence In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Human Genetic Tests
• Microbial Tests
• In Vitro Diagnostics
• System for the Analysis of Solid Tumors
• Hybridization Technique
• Detection of Long Non-
• Coding DNA
• Coding RNA
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Michelle Thoras
201 Spear Street 1100,
Suite 3036, San Francisco,
CA 94105, United States
Tel: 1-415-349-0054
Toll Free: 1-888-928-9744
Mail: [email protected]
This user is on the @buildawhale blacklist for one or more of the following reasons:
Downvoting a post can decrease pending rewards and make it less visible. Common reasons:
Submit